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DTX on PC3 cell growth inhibition and similar results were
recorded after transfection of PC3 cells with shCYR61. In conclu-
sion, it is possible to design new molecular rationale-based ther-
apeutic strategies in androgen-independent prostate cancer.
doi:10.1016/j.ejcsup.2008.06.047
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Background: Docetaxel (DTX) is effective in the treatment of
hormone-refractory prostate carcinoma patients (HRPC). In vitro
data suggest that zoledronic acid (ZOL) and DTX have a synergis-
tic effect on the growth inhibition of prostate cancer cells and
that such synergism is sequence-dependent. Therefore, prostate
cancer is a suitable target for a pharmacological combination
between DTX and ZOL. On the basis of these considerations, a
phase I trial on the combination of ZOL and DTX was designed
in the treatment of HRPC.
Materials: A dose-escalation of DTXwas planned in combination
withafixeddoseofZOL (2 mg),bothadministeredevery14days.The
following two different sequences of the two drugs were explored:
Sequence A: DTX at day 1 followed by ZOL at day 2. Sequence B:
ZOL at day 1 followed by DTX at day 2. The first dose level of DTX
was 30mg/m2 with a planned dose escalation of 10mg/m2 for each
level until 50 mg/m2. Serumcytokines and PBMCwere also collected
prior and after the different treatments at each cycle.
Results: Up to now, we have enrolled 22 patients. Six patients at
third level (Sequence B) were required due a case of vascular tox-
icity of grade III (deep thrombo-phlebitis). A different pattern of
circulating sangiogenic factors (interleukin 8 and 12, VEGF, PDGF),
cytokines (TNF-a, IFN-c, interleukin 6 and 4) and gamma/delta T
lymphocyte subpopulation was recorded in the two different
sequences. The study is still ongoing and further results will be
presented at GOIM meeting.
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Background: Approximately, 30–40% of patients with a superfi-
cial bladder cancer treated with Bacille Calmette-Guerin(BCG) or
epirubicin do not respond and other 35% of initial responders
have a relapse within 5 years. We compare the therapeutic effi-
cacy and toxicity of intravescical instillations of Gemcitabine
(GEM) with mitomycin C (MMC) in patients with a recurrent
superficial bladder cancer.
Methods: Patients with a history of a recurrent Ta-T1, G1-G2
bladder transitional cell carcinoma, previously treated were
enrolled in the study. The patients received a 6-week course of
GEM instillations or 4-week course of MMC. In both arms, for the
initial responderswho remained free of recurrences, maintenance
therapy consisted of a 10 monthly treatment during the first year.
All patients were followed every 6 months by cystourethroscopy.
Results: A total of 120 patients were enrolled and randomly
assigned to either the MMC treatment arm or Gemcitabine treat-
ment arm. The remaining 109 patients (55 in MMC arm and 54 in
Gemcitabine arm) were evaluable. The median duration of follow-
up was (identical for both groups) 34 months.
Of the 54 patients in the Gemcitabine group 42(78%) remained
free of recurrence compared to 37 (67%) of the 55 patients treated
with MMC (p = 0.05). Among patients with recurrences, 10 in the
MMC arm and 6 in the Gemcitabine group had progressive disease
by stage: either local urothelial spread, or muscle infiltration, in 5
and 3, respectively. Local toxicity in both treatment groups was
acceptable. The incidence of. chemical cystitis in MMC arm was
statisticantly different from that in GEM group (p = 0,012).
Conclusions: Gemcitabine for its better clinical activity and
favourable toxicity profile than MMC, is a logical candidate for
intravescical therapy in refractory transitional cell patients. Final
results will be presented at 2008 ASCO Meeting.
doi:10.1016/j.ejcsup.2008.06.049
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Background: In the last few years, high dose chemotherapy
(HDCT) with haematopoietic stem cell transplantation (HSCT)
has been increasingly investigated as a therapeutic option for
early or late intensification in patients with poor prognosis germ
cell tumor (GCT) or in pats who relapse or who have a partial
response after a first line chemotherapy.
Methods: Eleven patients were treated with three cycles of VeIP
(ifosfamide 1200 mg/m2, mesna 1200 mg/m2, cisplatin 20 mg/m2,
days 1–5 and vinblastine 0.11 mg/kg, days 1–2) and one course
of HDCT: Carbo-PEC (carboplatin 400–550 mg/m2/day on day 1,
etoposide 450 mg/m2/day, cyclophosphamide 1600 mg/m2/day
and mesna 3600 mg/m2 on days 1–4) followed on day 7 by HSCT.
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